Fibrogen INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
FGEN
Fibrogen INCArmistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, disclosing beneficial ownership of 9.88% of Kyntra Bio, Inc.'s common stock.
FGEN
Fibrogen INCArmistice Capital, LLC and Steven Boyd have jointly reported a beneficial ownership of 9.88% in Kyntra Bio, Inc., holding 400,000 shares.
FGEN
Fibrogen INCArmistice Capital, LLC and Steven Boyd have disclosed a 9.35% beneficial ownership stake in FibroGen Inc., holding 378,000 shares of common stock.
FGEN
Fibrogen INCArmistice Capital, LLC and Steven Boyd have disclosed a beneficial ownership of 8.31% in FibroGen Inc., totaling 336,000 shares of common stock.
FGEN
Fibrogen INCThe Vanguard Group has filed an amendment to its Schedule 13G, disclosing a beneficial ownership of 4.4% in FibroGen Inc.'s common stock.
FGEN
Fibrogen INCArmistice Capital, LLC and Steven Boyd have reported an 8.42% beneficial ownership stake in FibroGen Inc., holding 8,500,000 shares as of March 31, 2025.
FGEN
Fibrogen INCInvestment firm Armistice Capital, LLC and its managing member Steven Boyd have disclosed a 6.75% beneficial ownership stake in FibroGen, Inc., holding 6,800,000 shares as of December 31, 2024.
FGEN
Fibrogen INCPRIMECAP Management Co/CA/ has filed an amended Schedule 13G, disclosing a 4.58% beneficial ownership stake in FibroGen, Inc. as of December 31, 2024.